Compare Eversource Energy (D/B/A) Common Stock (ES) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eversource Energy (D/B/A) Common Stock vs Illumina, Inc. — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $67.32 (market cap $25.11B), while Illumina, Inc. trades at $270.48 (market cap $41.04B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.72% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and Illumina, Inc. for 84 Days on average.
| ES | ILMN | |
|---|---|---|
Market Cap | $25.11B | $41.04B |
Volume | 3,164,400 | 2,120,523 |
Sector | Utilities | Health |
52-Week High | $76.21 | $293.69 |
52-Week Low | $63.28 | $93.00 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $55.18B | $42.39B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Illumina (ILMN) trades at $271.18, down 1.99% but near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has delivered three consecutive earnings beats. Fundamentals improved significantly with 2025 net income turning positive at $850M after years of losses, while revenue remains stable around $4.3B. Valuation metrics appear elevated with P/E at 50.7 and P/S at 9.31, reflecting premium pricing for growth expectations.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and S&P 500 inclusion providing institutional support. Key catalysts include AI integration in genomics and expanding drugmaker partnerships. Risks include China market headwinds, cost volatility pressuring margins, and high valuation requiring sustained growth. Cash flow stability improved with $291M net inflow in 2025 after previous volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
